Find Specific Jobs
Abraxis BioScience main competitors are bluebird bio, Akebia Therapeutics, and Hoffmann-LA Roche Inc.
Competitor Summary. See how Abraxis BioScience compares to its main competitors:
|Company||Founding Date||Zippia Score||Headquarters||# of Locations||Revenue||Employees|
|Los Angeles, CA||1||$359.0M||885|
|New Haven, CT||1||$131.4M||83|
|South San Francisco, CA||1||$8.5M||61|
|New York, NY||1||$860,000||17|
|San Diego, CA||1||$8.5M||153|
|New York, NY||1||$86.7M||43|
|Company||Highest Salary||Hourly Salary|
Hoffmann-LA Roche Inc
Clinical Supplies Management
Sun Pharmaceutical Industries Inc.
|Sun Pharmaceutical Industries Inc.||62%||38%|
|Company||White||Hispanic or Latino||Black or African American||Asian||Unknown||Diversity Score|
Mr Butler joined Akebia as President and CEO in September, 2013. He has more than 25 years of experience leading the development, launch and commercialization of innovative therapies. He served as CEO of Inspiration Biopharmaceuticals, a company focused on developing products for patients with hemophilia, from 2011 until 2013. He led the sale of the company’s assets, including the company’s lead asset to Baxter Corporation, the world leader in hemophilia. The value of the transactions should total over $1 billion to Inspiration’s shareholders. From 1997 to 2011, Mr Butler held various positions at Genzyme Corporation, one of the world’s largest biotechnology companies. While at Genzyme, he most recently served as President of the company’s rare genetic diseases business, which has developed and commercialized first-to-market, transformative therapies for small patient populations. Mr Butler also led the company’s renal, endocrinology, and cardiovascular businesses, growing the division to $1 billion in revenue. Earlier in his career, he held sales and marketing positions at Amgen and Hoffmann-La Roche. He has spent over twenty years working to improve the lives of patients with kidney disease. He served in a number of commercial roles while at Amgen for Epogen® and he led the renal business at Genzyme which brought Renagel®, Renvela®, and Hectorol® to these patients. He currently serves as the chairman of the American Kidney Fund board of trustees. The AKF is the leading patient focused charitable organization in kidney disease, providing assistance to one in 5 patients on kidney dialysis in the US. Mr Butler received his BA degree in Chemistry from Manhattan College and his MBA degree from Baruch College.
Yvonne Greenstreet is a COO at ALNYLAM PHARMACEUTICALS, INC..
Nick Leschly has served as our chief bluebird since September 2010. Formerly, Nick was a partner and founding member of Third Rock Ventures in 2007. Nick played an integral role in the overall formation, development and business strategy of several of Third Rock’s portfolio companies, including Agios Pharmaceuticals, Inc. and Edimer Pharmaceuticals, Inc. Prior to joining Third Rock, he worked at Millennium Pharmaceuticals, leading several early-stage drug development programs and served as the product leader for VELCADE. Nick also founded and served as chief executive officer of MedXtend Corporation. He received his B.S. in molecular biology from Princeton University and his MBA from Wharton Business School. He currently serves as a board member of the Biotechnology Innovation Organization (BIO) and Synlogic Therapeutics.
Satya Chava is a Chief Executive Officer at Aptuit and is based in Greenwich, CT area.
Ronald Piervincenzi is a Chief Executive Officer at United States Pharmacopeia and is based in Rockville, Maryland. He has worked as Principal at McKinsey & Company and VP Development Sciences Business Strategy at BIOGEN INC.. Ronald studied at Hofstra University between 1989 and 1993 and Duke University between 1993 and 2000.